Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more)
Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Hemostemix Inc
V.HEM
Alternate Symbol(s):
HMTXF
Healthcare
Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including...
angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01, its lead clinical-stage candidate, is an autologous cell therapy for the treatment of critical limb ischemia. ACP-01 is in a Phase 2 clinical trial in Canada and the United States. Its technology includes methods for collecting the synergetic cell population and manufacturing a personalized regenerative therapy that can be administered to a patient within seven days of the initial cell collection. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd. and PreCerv Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:HEM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 23, 2022 2:28pm
Hemostemix owns over 91 patents
The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell
...more
(6)
•••
Tradeconnects
X
View Profile
View Bullboard History
Post by
Tradeconnects
on Jun 23, 2022 2:21pm
Hemostemix Announces Closing of UNIT Private Placement
https://www.newsfilecorp.com/redirect/gxkwMHKrkx
Fintech Select LTD. Publishes Results for Fiscal Year 2023
posted May 01, 2024 9:00am by
Fintech Select Ltd.
-
|
Under the leadership of Fintech Select's management, the Company achieved a significant milestone in revenue generation, reaching $3,822,182 for fiscal year 2023, compared to $2,587,867 in 2022. Management is confident this 47% increase on a year-over-year basis ...read more
(7)
•••
TRADERCONNECTS
X
View Profile
View Bullboard History
Post by
TRADERCONNECTS
on Jun 23, 2022 1:49pm
$HEM recoups legal guardianship of its lost intellectual pro
The company has legally retrieved all intellectual data related to stage 2 clinical trial data, along with all previous data from Hemostemix Israel and the randomized table needed to evaluate ACP-01
...more
(24)
•••
robert345
X
View Profile
View Bullboard History
Post by
robert345
on Jun 23, 2022 12:41pm
$HEM announcement related to the Stock Options Grant
Hemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 23, 2022 12:06pm
Hemostemix informs regarding non-brokered private placement
Hemostemix Inc. announces a non-brokered private placement of up to 15 Million Units priced in the context of the market.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 23, 2022 11:58am
The approval of offering by TSX-V
The offering is subject to all the necessary regulatory approvals including acceptance from the exchange. All securities issued in connection with the offering will be subject to a four-month hold
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 23, 2022 11:47am
Hemostemix Announces the Incorporation of PreCerv Inc.
$HEM has announced it has incorporated PreCerv Inc. as a wholly owned subsidiary. PreCerv will obtain a license to NCP-01 and its autologous stem cell technologies.
(42)
•••
ENEMENEMYNEMO
X
View Profile
View Bullboard History
Post by
ENEMENEMYNEMO
on Jun 23, 2022 8:43am
PP
PP closed... less money earned but maybe less needed!!! and less dilution. WalterTheDawg Has a PM.
(2)
•••
zames007
X
View Profile
View Bullboard History
Post by
zames007
on Jun 23, 2022 7:52am
$HEM announced the addition of a wholly owned subsidiary
Hemostemix recently announced the incorporation of PreCerv Inc. (A wholly owned subsidiary of Hemostemix). Hemostemix will grant PreCerv a global field of use licence for NCP-01 and its autologous
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 23, 2022 7:19am
Hemostemix reclaims possession of all its lost intellectual
All the intellectual data including all phase 2 clinical trial data, all the historical data from hemostemix Israel, and the randomized table required to analyze North-American and South-African ACP
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 23, 2022 6:57am
Hemostemix regains legal possession of all its missing intel
All the intellectual data including all phase 2 clinical trial data, all the historical data from hemostemix Israel, and the randomized table required to analyze North-American and South-African ACP
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Jun 22, 2022 4:03pm
New Press Release - Hemostemix Announces Closing of UNIT Private Placement
Calgary, Alberta--(Newsfile Corp. - June 22, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it closed the first tranche of its non-brokered private placement of units ("Units") announced on May 19, 2022, for gross proceeds of $690,388.80 ...
read article.
(13)
•••
trade007
X
View Profile
View Bullboard History
Post by
trade007
on Jun 22, 2022 3:25pm
Hemostemix to reimburse the finder’s fees
Hemostemix had planned to pay the finder’s fees of 8% by using the gross proceeds in connection with the current filing, clinical trial costs, regulatory fees, etc. with the balance to be used for
...more
(13)
•••
trade007
X
View Profile
View Bullboard History
Post by
trade007
on Jun 22, 2022 3:09pm
Data audit efficiently performed, results came out to be aut
Hemostemix have been handed back its intellectual property consisting of all the clinical trial data of ACP-01 which was long unlawfully held by Accudata and Aspire Health Science, the data audit post
...more
(24)
•••
robert345
X
View Profile
View Bullboard History
Post by
robert345
on Jun 22, 2022 2:25pm
$HEM regains legal custody of its lost intellectual property
The company has legally retrieved all intellectual data related to stage 2 clinical trial data, along with all previous data from Hemostemix Israel and the randomized table needed to evaluate ACP-01
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
This profitable gold stock is on its way up
Mullen Group Ltd. Reports 2024 First Quarter Financial Results
This Gambling Tech Stock is Future-Proofing the World’s Casinos and has No Direct Competition
Silvercorp to Acquire Adventus, Creating a Geographically Diversified Mining Company
Revolutionary Tech Company Announces Fourth Quarter and Full Year 2023 Results
Drill Permit Approval Received for New Mexico Lithium Project